Hypertrophic Cardiomyopathy and the Likelihood of Cardiac Arrest Outside a Hospital Setting - Report - MDSpire

Hypertrophic Cardiomyopathy and the Likelihood of Cardiac Arrest Outside a Hospital Setting

  • By

  • Rasmus Bork Dinesen

  • Deepthi Rajan

  • Christian Torp-Pedersen

  • Niels Risum

  • Peder Emil Warming

  • Jacob Tfelt-Hansen

  • April 29, 2026

  • 0 min

Share

Clinical Report: Hypertrophic Cardiomyopathy and the Likelihood of Cardiac Arrest

Overview

This study investigates the long-term risk of out-of-hospital cardiac arrest (OHCA) in patients with hypertrophic cardiomyopathy (HCM) compared to matched controls without HCM. Findings indicate that while the incidence of sudden cardiac death has declined, OHCA remains a significant risk in this population.

Background

Hypertrophic cardiomyopathy (HCM) is a hereditary cardiac condition with a prevalence of 1 in 500 individuals, characterized by an unpredictable clinical course that can lead to severe outcomes, including sudden cardiac death (SCD). Despite advancements in treatment and preventive care, SCD continues to pose a risk, particularly due to the potential for OHCA. Understanding the long-term risk of OHCA in HCM patients is critical for improving patient management and outcomes.

Data Highlights

No numerical data available in the source material.

Key Findings

  • The study utilized a nationwide cohort of patients diagnosed with HCM to assess the risk of OHCA.
  • Patients with HCM were matched with controls based on sex, age, comorbidities, and medication use.
  • OHCA was defined as cases where resuscitation was attempted, excluding those where it was not.
  • Long-term follow-up was conducted until the occurrence of OHCA, death, or end of the observation period.
  • The study highlights the need for ongoing surveillance and risk assessment in patients with HCM.

Clinical Implications

Clinicians should be aware of the heightened risk of OHCA in patients with HCM and consider appropriate monitoring and preventive strategies. The findings underscore the importance of individualized risk assessment and the potential need for implantable cardioverter-defibrillators in high-risk patients.

Conclusion

The study provides valuable insights into the long-term risk of OHCA in patients with HCM, emphasizing the need for continued vigilance in managing this population. Further research is warranted to refine risk stratification and improve patient outcomes.

References

  1. Atlantic Health System, Morristown Medical Center, 2023 -- New Guidelines Offer Promise for Patients with Hypertrophic Cardiomyopathy
  2. JAMA Network Open, 2023 -- Is Poor Recognition of Out-of-Hospital Cardiac Arrest to Blame for Worse Rates of Survival at Night?
  3. Clinical Research in Cardiology, 2023 -- Analysis of Factors Surrounding Sudden Cardiac Arrest in a Young German Population: Systematic Findings and Consequences
  4. American College of Cardiology, 2024 -- 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
  5. Clinical Research in Cardiology — Apical Hypertrophic Cardiomyopathy: Understanding Pathophysiology, Diagnostic Approaches, and Treatment Strategies
  6. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy - American College of Cardiology
  7. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy - PubMed
  8. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial - PubMed

Original Source(s)

Related Content